To address skin and acne issues, it's critical to address the underlying causes of those symptoms.
In women with PCOS, acne symptoms are typically caused by two main things:
1. Excess Androgens
2. Inflammation in the body
This bundle aims to address both of those areas as well as repairing the skin from existing acne scarring.
References (For The Nerds Like Us 🤓)
Chuan SS, Chang RJ. Polycystic ovary syndrome and acne. Skin Therapy Lett. 2010 Nov-Dec;15(10):1-4. PMID: 21076799.
Gainder S, Sharma B. Update on Management of Polycystic Ovarian Syndrome for Dermatologists. Indian Dermatol Online J. 2019 Mar-Apr;10(2):97-105. doi: 10.4103/idoj.IDOJ_249_17. PMID: 30984582; PMCID: PMC6434760.
Housman E, Reynolds RV. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations. J Am Acad Dermatol. 2014 Nov;71(5):847.e1-847.e10; quiz 857-8. doi: 10.1016/j.jaad.2014.05.007. Epub 2014 Oct 15. PMID: 25437977.
Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi Yarandi R, Saei Ghare Naz M, Carmina E. Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systemic review and meta-analysis. Gynecol Endocrinol. 2021 May;37(5):392-405. doi: 10.1080/09513590.2020.1859474. Epub 2020 Dec 23. PMID: 33355023.
Franik G, Bizoń A, Włoch S, Kowalczyk K, Biernacka-Bartnik A, Madej P. Hormonal and metabolic aspects of acne vulgaris in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2018 Jul;22(14):4411-4418. doi: 10.26355/eurrev_201807_15491. PMID: 30058676.
🎓[1] Nestler, J.E.; Unfer, V. Reflections on Inositol(s) for PCOS Therapy: Steps toward Success. Gynecol. Endocrinol. 2015, 31, 501–505
🎓[2] Facchinetti, F.; Orrù, B.; Grandi, G.; Unfer, V. Short-Term Effects of M**tformin and Myo-Inositol in Women with Polycystic Ovarian Syndrome (PCOS): A Meta-Analysis of Randomized Clinical Trials. Facchinetti F1, Orrù B2, Grandi G1, Unfer V3. Gynecol. Endocrinol. 2019, 35, 198–206
🎓[3] Laganà, A.S.; Rossetti, P.; Buscema, M.; La Vignera, S.; Condorelli, R.A.; Gullo, G.; Granese, R.; Triolo, O. Metabolism and Ovarian Function in PCOSWomen: ATherapeutic Approach with Inositols. Int. J. Endocrinol. 2016, 2016, 6306410.
🎓[4] Unfer V, Carlomagno G, Papaleo E, Vailati S, Candiani M, Baillargeon JP. Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod Sci. 2014;21(7):854-8.
🎓[5] Unfer, V.; Facchinetti, F.; Orrù, B.; Giordani, B.; Nestler, J. Myo-Inositol Effects in Women with PCOS: A Meta-Analysis of Randomized Controlled Trials. Endocr. Connect. 2017, 6, 647–658.
🎓[6] Benelli, E.; Del Ghianda, S.; Di Cosmo, C.; Tonacchera, M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. Int. J. Endocrinol. 2016, 2016, 3204083
🎓[7] Bevilacqua, A.; Carlomagno, G.; Gerli, S.; Oliva, M.M.; Devroey, P.; Lanzone, A.; Soulange, C.; Facchinetti, F.; Di Renzo, G.C.; Bizzarri, M.; et al. Results from the International Consensus Conference on Myo-Inositol and D-Chiro-Inositol in Obstetrics and Gynecology-Assisted Reproduction Technology. Gynecol. Endocrinol. 2015, 31, 441–446.
🎓[8] Colazingari, S.; Treglia, M.; Najjar, R.; Bevilacqua, A. The Combined Therapy Myo-Inositol plus D-Chiro-Inositol, Rather than D-Chiro-Inositol, Is Able to Improve IVF Outcomes: Results froma Randomized Controlled Trial. Arch. Gynecol. Obstet. 2013, 288, 1405–1411.
🎓[9] Ravanos K, Monastra G, Pavlidou T, Goudakou M, Prapas N. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? European review for medical and pharmacological sciences. 2017;21(23):5491-8.
🎓[10] Dinicola, S.; Chiu, T.T.Y.; Unfer, V.; Carlomagno, G.; Bizzarri, M. The Rationale of the Myo-Inositol and D-Chiro-Inositol Combined Treatment for Polycystic Ovary Syndrome. J. Clin. Pharmacol. 2014, 54, 1079–1092
🎓[11] Bevilacqua, A.; Dragotto, J.; Giuliani, A.; Bizzarri, M. Myo-Inositol and D-Chiro-Inositol (40:1) Reverse
Histological and Functional Features of Polycystic Ovary Syndrome in a Mouse Model. J. Cell. Physiol. 2019,
234, 9387–9398.
🎓[12] Diamanti-Kandarakis, E.; Dunaif, A. Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocr. Rev. 2012, 33, 981–1030.
🎓[13] Abdel Hamid AMS, Ismail Madkour WA, Borg TF. Inositol versus M*****min administration in polycystic ovary syndrome patients: a case–control study. Journal of Evidence-Based Women’s Health Journal Society. 2015;5(3). https://journals.lww.com/ebjwh/Fulltext/2015/08000/Inositol_versus_***_administration_in.2.aspx
[1] Thota RN, Acharya SH, Garg ML. Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial. Lipids Health Dis. 2019 Jan 26;18(1):31. doi: 10.1186/s12944-019-0967-x. PMID: 30684965; PMCID: PMC6347796.
[2] Zafari M, Behmanesh F, Agha Mohammadi A. Comparison of the effect of fish oil and ibuprofen on treatment of severe pain in primary dysmenorrhea. Caspian J Intern Med. 2011 Summer;2(3):279-82. PMID: 24049587; PMCID: PMC3770499.
[3] Jung JY, Kwon HH, Hong JS, Yoon JY, Park MS, Jang MY, Suh DH. Effect of dietary supplementation with omega-3 fatty acid and gamma-linolenic acid on acne vulgaris: a randomised, double-blind, controlled trial. Acta Derm Venereol. 2014 Sep;94(5):521-5. doi: 10.2340/00015555-1802. PMID: 24553997.